Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularSTU:LHU +0.73%98 EV-to-FCF is 22.72 as of Aug. 07, 2026, which is 43% below its 10-year median of 39.76. GuruFocus rates STU:LHU with a GF Score™ of 98/100 and a GF Value™ of €81.33 (Modestly Undervalued). Among 413 Medical Devices & Instruments companies, LeMaitre Vascular ranks better than 52.3% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, LeMaitre Vascular's Enterprise Value is €1,438.4 Mil.
LeMaitre Vascular's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €63.3 Mil. Therefore, LeMaitre Vascular's EV-to-FCF for today is 22.72.
The historical rank and industry rank for LeMaitre Vascular's EV-to-FCF or its related term are showing as below:
STU:LHU'
s EV-to-FCF Range Over the Past 10 Years
Min: 22.4 Med: 39.76 Max: 80.27
Current: 22.52
During the past 13 years, the highest EV-to-FCF of LeMaitre Vascular was 80.27. The lowest was 22.40. And the median was 39.76.
STU:LHU's EV-to-FCF is ranked better than 52.3% of 413
companies
in the Medical Devices & Instruments industry
Industry Median: 23.86
vs STU:LHU: 22.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LeMaitre Vascular's PE Ratio (TTM) for today is calculated as:
LeMaitre Vascular's share price for today is €69.00.
LeMaitre Vascular's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.450.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
LeMaitre Vascular EV-to-FCF Related Terms
LeMaitre Vascular EV-to-FCF Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's EV-to-FCF falls into.
LeMaitre Vascular's current Enterprise Value is €1,438.4 Mil.
LeMaitre Vascular's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €63.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (STU:LHU) has a EV-to-FCF of 22.72 as of Aug. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on LeMaitre Vascular and its competitors. This is 43% below median its historical median of 39.76. Over the past decade, LeMaitre Vascular's EV-to-FCF has ranged from 22.40 to 80.27. According to the industry distribution chart, LeMaitre Vascular ranks #197 out of 413 companies in the Medical Devices & Instruments industry, placing it in the top 47.7%.
Is LeMaitre Vascular's EV-to-FCF too high?
LeMaitre Vascular's current EV-to-FCF of 22.72 is 43% below median its 10-year median of 39.76. Over the past 10 years, this metric has ranged from a low of 22.40 to a high of 80.27. The Medical Devices & Instruments industry median EV-to-FCF is 23.86. LeMaitre Vascular's value of 22.72 is 4.8% below this industry median. Based on the distribution chart, LeMaitre Vascular ranks #197 out of 413 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, LeMaitre Vascular has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's EV-to-FCF compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #197 out of 413 companies for EV-to-FCF. This puts LeMaitre Vascular in the upper half of its industry. The industry median EV-to-FCF is 23.86. LeMaitre Vascular's value of 22.72 is 4.8% below this benchmark. Historically, LeMaitre Vascular's own EV-to-FCF has ranged from 22.40 to 80.27 over the past decade. While the company's 10-year median is 39.76 vs. the industry median of 23.86, LeMaitre Vascular has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.86, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current EV-to-FCF of 22.72 is 4.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current EV-to-FCF is 22.72, which is 43% below median its own 10-year median of 39.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (STU:LHU) is currently considered Modestly Undervalued. The stock's GF Value™ is €81.33, compared to a current price of €69.00 — trading 15.2% below its estimated fair value. The current EV-to-FCF is 22.72, which is 43% below median its 10-year median of 39.76 and 4.8% below the Medical Devices & Instruments industry median of 23.86. LeMaitre Vascular's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For LeMaitre Vascular (STU:LHU), the current EV-to-FCF is 22.72 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (STU:LHU) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of €69.00 is trading 15.2% below its estimated GF Value™ of €81.33.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for STU:LHU:
EV-to-FCF: 22.72 (43% below median its 10-year median of 39.76)
GF Value™: €81.33 vs. price of €69.00 (15.2% below fair value)
Industry Position: 4.8% below the Medical Devices & Instruments median (#197 of 413)
No single metric tells the full story. See the STU:LHU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
98GF Score
Get the complete analysis for STU:LHU
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LHU has been successfully added to your 
